---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-027190"
form_type: "8-K"
ticker: "AQST"
cik: "0001398733"
company_name: "Aquestive Therapeutics, Inc."
filed_at: "2022-10-27T23:59:59+00:00"
generated_at: "2026-06-22T23:53:25.616956+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aquestive licenses Sympazan to Assertio for $9M upfront; up to $6M milestone

## Summary
- Exclusive worldwide license of Sympazan (clobazam) oral film to Otter Pharmaceuticals (Assertio) for LGS.
- Aquestive receives $9M upfront and will get $6M milestone upon patent allowance (notice already received Oct 27, 2022).
- Aquestive will also receive royalties from Assertio and serve as exclusive manufacturer under long-term supply agreement.
- Deal provides non-dilutive financing to focus on development of AQST-109 (epinephrine sublingual film) for anaphylaxis.

## SEC filing metadata
- accession: 0001628280-22-027190
- form_type: 8-K
- ticker: AQST
- cik: 0001398733
- company_name: Aquestive Therapeutics, Inc.
- filed_at: 2022-10-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1398733/000162828022027190/0001628280-22-027190-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1398733/000162828022027190/aqst-20221026.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-027190
- JSON: https://secwatch.observer/filing/0001628280-22-027190.json
- Plain text: https://secwatch.observer/filing/0001628280-22-027190.txt

## Key facts
- Material Agreements
  Aquestive Therapeutics, Inc. entered into Assertio License Agreement with Otter Pharmaceuticals, LLC, a subsidiary of Assertio Holdings, Inc. valued at $9.0 million (effective 2022-10-26).
  - Action: entry
  - Agreement: license
  - Counterparty: Otter Pharmaceuticals, LLC, a subsidiary of Assertio Holdings, Inc.
  - Value: $9.0 million
  - Effective: 2022-10-26
  source text: Effective October 26, 2022, Aquestive Therapeutics, Inc. ("Aquestive" or the “Company”) entered into a License Agreement with Otter Pharmaceuticals, LLC, a subsidiary of Assertio Holdings, Inc. (NASDAQ: ASRT) (“Assertio”), a specialty pharmaceutical company offering differentiated products to patients, to license Sympazan® (clobazam) oral film for the adjunctive treatment of seizures associated with Lennox‐Gastaut syndrome (LGS) in patients aged two years of age or older (the "Assertio License Agreement").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1398733/000162828022027190/0001628280-22-027190-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.